Arrowhead Research Corp. (NASDAQ:ARWR) Q1 2019 Earnings Conference Call Transcript
Feb 07, 2019 • 04:30 pm ET
Ladies and gentlemen, welcome to the Arrowhead Pharmaceutical's conference call. (Operator Instructions)
I will now hand the conference call over to Vincent Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead, Vince.
Thanks, Lauren. Good afternoon, everyone. Thank you for joining us today to discuss Arrowhead's results for its fiscal 2019 first quarter ended December 31, 2018. With us today from management are our President and CEO, Dr. Christopher Anzalone, who will provide an overview of the quarter; Dr. Bruce Given, our Chief Operating Officer and Head of R&D, who will discuss our clinical programs; and Ken Myszkowski, our Chief Financial Officer, who will give a review of the financials. We will then open up the call to your questions.
Before we begin, I would like to remind you that comments made during today's call contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
All statements other than statements of historical fact, including without limitation, those with respect to Arrowhead's goals, plans and strategies are forward-looking statements. These include statements regarding our expectations around the development, safety and efficacy of our drug candidates, projected cash runway and expected future development activities. These statements represent management's current expectations and are inherently uncertain. Thus, actual results may differ materially. Arrowhead disclaims any intent and undertakes no duty to update any of the forward-looking statements discussed on today's call. You should refer to the discussions under Risk Factors in Arrowhead's annual report on Form 10-K and the company's subsequent quarterly reports on Form 10-Q for additional matters to be considered in this regard, including the risks and other considerations that could cause actual results to vary from the presently expected results expressed in today's call.
With that said, I'd like to turn the call over to Christopher Anzalone, President and CEO of the company. Chris?
Thanks, Vince. Good afternoon, everyone, and thank you for joining us today. 2018 was a very productive year for us. A year ago, we were preparing to start first-in-human clinical studies for the first two candidates built on the TRiM platform, and today, there are five candidates either in or approaching the clinic. ARO-HBV against chronic hepatitis B infection is in a Phase I/II study and is partnered with Janssen. ARO-HBV will now be referred to as JNJ-3989.
The second candidate is ARO-AAT against a rare genetic liver disease associated with alpha-1 antitrypsin, or AAT deficiency, which has completed its Phase I study. We are actively working with the FDA to get feedback on potential endpoints and design of our next study.
The third candidate is AMG 890 against cardiovascular disease and is partnered with Amgen. Amgen is evaluating AMG 890 in a Phase I study to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects.
The fourth candidate is ARO-ANG3 against dyslipidemia in a Phase I study in healthy adult volunteers and dyslipidemic patients.
And the fifth candidate is ARO-APOC3 against